 AGOURA HILLS, California, Feb. 02, 2021 GLOBE NEWSWIRE -- Mateon Therapeutics, Inc. OTCQB:MATN Mateon, a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that its ARTI-19 trial, evaluating ARTIVedaTM PulmoHealTM against COVID-19 in India, has completed randomization of all 120 patients and final analysis is expected in March 2021. Simultaneously, Mateon published positive interim data as preprint at . Once the article is published in a peer-reviewed journal, medRxiv will update the preprint with a link to the published version. 